Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as arzoxifene hydrochloride, LY353381
arzoxifene · 7 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Arzoxifene | DRUG | 20 mg, oral, tablet, once a day for 52 weeks |
| Raloxifene | DRUG | 60 mg, oral, tablet, once a day for 52 weeks |
| Placebo | DRUG | oral, tablet, once a day for 36 months |
| LY353381 | DRUG | - |
| tamoxifen | DRUG | - |
| arzoxifene hydrochloride | DRUG | - |
Inclusion Criteria: * Must have osteoporosis * Must be between 50 and 75 years old and be able to walk * Have at least two of your back bones that can be x-rayed * Have not had a period in at least two years * Be willing to have blood tests Exclusion Criteria: * Have a bone disease other than ost...
Arzoxifene is an investigational small molecule developed by Eli Lilly and Company. It has been studied in women for osteoporosis, postmenopausal bone loss, and postmenopausal osteoporosis, and it has also been explored in endometrial and ovarian cancer research. It is not an approved medicine and remains in clinical development.
Arzoxifene has been studied for osteoporosis and postmenopausal bone loss, and for postmenopausal osteoporosis. Research has also examined it in endometrial cancer and ovarian cancer. These uses are investigational, meaning arzoxifene is not approved for any indication and remains in clinical development.
Arzoxifene targets the estrogen receptors ESR2 and ESR1. It is classified as a modulator, meaning it interacts with these receptors rather than simply blocking or activating them. This receptor activity is the basis for its study in bone loss and in hormone related cancers.
Arzoxifene is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor behind the clinical research program for the drug.
Arzoxifene is in Phase 2 development and is not FDA approved. It is an investigational small molecule, and no active trials are currently listed. Completed studies include Phase 2 and Phase 3 trials, so the asset has not advanced to regulatory approval.
Arzoxifene has been studied in completed trials including NCT00767299 in Korean women with osteoporosis, NCT00383422 comparing it with raloxifene in postmenopausal osteoporosis, NCT00088010 on bone fractures and breast cancer incidence, and NCT00085956 on bone mass and the uterus.
Yes. Arzoxifene hydrochloride is another name for arzoxifene, the same investigational small molecule developed by Eli Lilly and Company. Searches for either name refer to the same drug asset and the same clinical research program.